

Dyax Corp.

300 Technology Square
Cambridge, MA 02139
phone (617) 225-2500
fax (617) 225-2501



IMPORTANT DRUG WARNING

Dear Healthcare Professional:

Dyax Corp. is writing to inform you of important safety information for KALBITOR[®] (ecallantide). KALBITOR is a subcutaneous injection indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age or older. Important safety information related to KALBITOR includes:

- The risk of anaphylaxis
- The need to distinguish signs and symptoms of anaphylaxis from HAE attacks

To ensure that the benefits of KALBITOR treatment outweigh the risks, the KALBITOR labeling includes a boxed warning concerning anaphylaxis, as follows:

WARNING: Anaphylaxis

Anaphylaxis has been reported after administration of KALBITOR[®]. Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema. Healthcare professionals should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema and patients should be monitored closely. Do not administer KALBITOR to patients with known clinical hypersensitivity to KALBITOR.

In 255 HAE patients treated with intravenous or subcutaneous KALBITOR in clinical trials, 10 patients (3.9%) experienced anaphylaxis. For the subgroup of 187 patients treated with subcutaneous KALBITOR, 5 patients (2.7%) experienced anaphylaxis. In clinical trials, when hypersensitivity was observed, it usually occurred immediately following exposure to KALBITOR, and always **within the first hour** following dosing.

In order to appropriately manage anaphylaxis, it must be recognized if it occurs. Because the signs and symptoms of HAE attacks may overlap with the signs and symptoms of anaphylaxis, there is a need to distinguish between serious hypersensitivity, including anaphylaxis and HAE attack symptoms.

Signs and symptoms that can be seen in either anaphylaxis or acute attacks of HAE include:

- erythema of the skin
- laryngeal edema
- dyspnea
- flushing
- stomach and gastrointestinal symptoms
- decreases in blood pressure

KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema. If a patient does not respond to an initial dose of KALBITOR, an additional dose of KALBITOR may be administered within a 24 hour period; before administering a repeat dose of KALBITOR, it is very important to assess the patient to assure that symptoms are reflective of an HAE attack and not a hypersensitivity reaction.

Please take time to read the enclosed KALBITOR Package Insert for full prescribing information and to review the Medication Guide with patients.

To report adverse events potentially associated with KALBITOR, please call Dyax Corp. at 1-888-452-5248. Alternatively, adverse event information may be reported to FDA's MedWatch Reporting System by:

- Phone at 1-800-FDA-1088 (1-800-332-1088)
- Facsimile at 1-800-FDA-0178 (1-800-332-0178)
- Mail using FDA Form 3500 located at <http://www.fda.gov/medwatch>

We invite you to contact Dyax Corp. at 1-888-452-5248 if you have any questions about KALBITOR or the information in this letter.

Sincerely,



Andrew Campbell, PhD
Sr. Director, Medical Affairs
Dyax Corp.

Enclosures: Full Prescribing Information including Medication Guide